Literature DB >> 8980109

Amino acids of the alpha1B-adrenergic receptor involved in agonist binding: differences in docking catecholamines to receptor subtypes.

A Cavalli1, F Fanelli, C Taddei, P G De Benedetti, S Cotecchia.   

Abstract

Site-directed mutagenesis and molecular dynamics analysis of the 3-D model of the alpha1B-adrenergic receptor (AR) were combined to identify the molecular determinants of the receptor involved in catecholamine binding. Our results indicate that the three conserved serines in the fifth transmembrane domain (TMD) of the alpha1B-AR play a distinct role in catecholamine binding versus receptor activation. In addition to the amino acids D125 in TMDIII and S207 in TMDV directly involved in ligand binding, our findings identify a large number of polar residues playing an important role in the activation process of the alpha1B-AR thus providing new insights into the structure/function relationship of G protein-coupled receptors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8980109     DOI: 10.1016/s0014-5793(96)01286-0

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  12 in total

1.  Exploration of the ligand binding site of the human 5-HT(4) receptor by site-directed mutagenesis and molecular modeling.

Authors:  J Mialet; Y Dahmoune; F Lezoualc'h; I Berque-Bestel; P Eftekhari; J Hoebeke; S Sicsic; M Langlois; R Fischmeister
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

2.  Differences in allosteric communication pipelines in the inactive and active states of a GPCR.

Authors:  Supriyo Bhattacharya; Nagarajan Vaidehi
Journal:  Biophys J       Date:  2014-07-15       Impact factor: 4.033

3.  Conserved Mechanism of Conformational Stability and Dynamics in G-Protein-Coupled Receptors.

Authors:  Supriyo Bhattacharya; Romelia Salomon-Ferrer; Sangbae Lee; Nagarajan Vaidehi
Journal:  J Chem Theory Comput       Date:  2016-10-17       Impact factor: 6.006

4.  5-HT1A receptor pharmacophores to screen for off-target activity of α1-adrenoceptor antagonists.

Authors:  Tony Ngo; Timothy J Nicholas; Junli Chen; Angela M Finch; Renate Griffith
Journal:  J Comput Aided Mol Des       Date:  2013-04-27       Impact factor: 3.686

5.  Modelling the interaction of catecholamines with the alpha 1A adrenoceptor towards a ligand-induced receptor structure.

Authors:  Gemma K Kinsella; Isabel Rozas; Graeme W Watson
Journal:  J Comput Aided Mol Des       Date:  2005-06       Impact factor: 3.686

6.  Ser203 as well as Ser204 and Ser207 in fifth transmembrane domain of the human beta2-adrenoceptor contributes to agonist binding and receptor activation.

Authors:  T Sato; H Kobayashi; T Nagao; H Kurose
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

7.  Agonist-specific coupling of a cloned human alpha1A-adrenoceptor to different second messenger pathways.

Authors:  Joanna Richardson; Heather Chatwin; Akira Hirasawa; Gozoh Tsujimoto; Peter D Evans
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-03-20       Impact factor: 3.000

8.  Investigation of D₁ receptor-agonist interactions and D₁/D₂ agonist selectivity using a combination of pharmacophore and receptor homology modeling.

Authors:  Marcus Malo; Lars Brive; Kristina Luthman; Peder Svensson
Journal:  ChemMedChem       Date:  2012-02-07       Impact factor: 3.466

Review 9.  Homology models of melatonin receptors: challenges and recent advances.

Authors:  Daniele Pala; Alessio Lodola; Annalida Bedini; Gilberto Spadoni; Silvia Rivara
Journal:  Int J Mol Sci       Date:  2013-04-12       Impact factor: 5.923

10.  Orthosteric binding of ρ-Da1a, a natural peptide of snake venom interacting selectively with the α1A-adrenoceptor.

Authors:  Arhamatoulaye Maïga; Jon Merlin; Elodie Marcon; Céline Rouget; Maud Larregola; Bernard Gilquin; Carole Fruchart-Gaillard; Evelyne Lajeunesse; Charles Marchetti; Alain Lorphelin; Laurent Bellanger; Roger J Summers; Dana S Hutchinson; Bronwyn A Evans; Denis Servent; Nicolas Gilles
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.